YOUR MS PATIENTS

MADE STRONG

Aim for over a decade of progression control.5,2 Treat First Line with OCREVUS®.

 

Ocrevus Global Home Page
The only aCD20 with over a DECADE of experience, delivered in just 10 minutes twice a year.1,2,3,4

OCREVUS®: START STRONG IN FIRST LINE, STAY STRONG

OCREVUS is the only aCD20 approved for both RMS and PPMS<sup>5,3</sup> with >11 years of clinical experience, now also delivered in just 10 minutes<sup>a</sup> twice a year.
EXTENSIVE EFFICACY

A decade of progression control and sustained activity control

A decade of progression control and sustained activity control
The window of opportunity is real: Starting OCREVUS early can delay over 8 years of disease progression in RMS
Uninterrupted living with OCREVUS® SC: Twice yearly, 10-min HCP-administered injection* without the need to split the first dose<sup>5</sup> allowing pwMS to forget about their treatment for six months.

MAXIMIZE FREEDOM

Uninterrupted living with OCREVUS® SC: Twice yearly, ~10 minute HCP-administered injection<sup>a</sup> without the need to split the first dose<sup>5</sup> allowing pwMS to forget about their treatment for six months.

PROVEN SAFETY PROFILE

  • Family planning pioneer

    Only aCD20 approved to use during breastfeeding<sup>c</sup> supported by human data<sup>6</sup> and allowing an administration-free pregnancy<sup>7</sup> with fewer missed doses and without compromising maternal disease control<sup>8</sup>

  • Safety confidence

    420,000+ pwMS<sup>9,10</sup> treated, long-term and consistent safety profile over 10 years in RMS and PPMS<sup>4</sup>
ocrevus

OCREVUS SC ADMINISTRATION

This guide presents instructions for healthcare professionals on how to handle, prepare and administer the OCREVUS® Subcutaneous injection.

Download administration guide
Patient Now

TALK TO YOUR PATIENT NOW

Leverage the patients guide to multiple sclerosis (MS) and starting treatment with OCREVUS®

Download patient guide
References

1. OCREVUS® (ocrelizumab) Subcutaneous SmPC, Roche Registration GmbH, Germany; 2. Hauser SL, et al. The Patient Impact of 11 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-Term Data from the Phase III OPERA and ORATORIO Studies. Presented at ECTRIMS, 9–11 October 2024, Copenhagen, Denmark. P1664; 3. FDA, OCREVUS ZUONOVO - HIGHLIGHTS OF PRESCRIBING INFORMATION, 2025; 4. Hauser SL, et al. Poster presented at ECTRIMS 2024 (P1664); 5. OCREVUS SC Summary of Product Characteristics; 6. Bove R, et al. Oral presented at ECTRIMS 2024 (O039); 7. Vukusic S, et al. Poster presented at ECTRIMS 2024 (P591); 8. Yeh et al., NeurolNeuroimmunolNeuroinflamm 2024; 9. Data on File: OCREVUS Patient Exposure Nov 2025; 10. Hauser SL, et al. Presented at: ECTRIMS 2024 (P300); 11. Newsome et al. Poster presented at ACTRIMS 2026 (P125).

aDoes not include all aspects of the treatment. Actual injection time may vary. Oral premedications are recommended at least 30 minutes before each injection with 20 mg of dexamethasone (or an equivalent corticosteroid) and an antihistamine (eg, desloratadine). OCREVUS SC is HCP administered and is recommended that post-injection monitoring with access to appropriate medical support to manage severe injection reactions for at least 1 hour after the first injection and at least 15 minutes after subsequent injections.

 

b11-year annualised event rate of 0.038 with IFN-OCR vs 0.029 with OCR-OCR accounts for delay of 8.2 years until next event.

 

cOcrelizumab can be used during breastfeeding starting a few days after birth per SMPC.